A detailed history of Black Rock Inc. transactions in Macrogenics Inc stock. As of the latest transaction made, Black Rock Inc. holds 5,401,728 shares of MGNX stock, worth $17.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,401,728
Previous 5,696,194 5.17%
Holding current value
$17.6 Million
Previous $83.8 Million 72.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.31 - $18.51 $974,682 - $5.45 Million
-294,466 Reduced 5.17%
5,401,728 $23 Million
Q1 2024

May 10, 2024

SELL
$9.77 - $21.47 $4.34 Million - $9.54 Million
-444,155 Reduced 7.23%
5,696,194 $83.8 Million
Q4 2023

Feb 13, 2024

BUY
$4.48 - $10.11 $467,349 - $1.05 Million
104,319 Added 1.73%
6,140,349 $59.1 Million
Q3 2023

Nov 13, 2023

BUY
$4.48 - $6.19 $177,381 - $245,086
39,594 Added 0.66%
6,036,030 $28.1 Million
Q2 2023

Aug 11, 2023

SELL
$4.62 - $7.54 $1,593 - $2,601
-345 Reduced 0.01%
5,996,436 $32.1 Million
Q1 2023

May 12, 2023

BUY
$4.82 - $7.24 $30,250 - $45,438
6,276 Added 0.1%
5,996,781 $43 Million
Q4 2022

Feb 13, 2023

BUY
$3.34 - $6.98 $893,650 - $1.87 Million
267,560 Added 4.68%
5,990,505 $40.2 Million
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $1.12 Million - $1.94 Million
372,141 Added 6.95%
5,722,945 $19.8 Million
Q2 2022

Aug 12, 2022

BUY
$2.25 - $9.99 $413,784 - $1.84 Million
183,904 Added 3.56%
5,350,804 $15.8 Million
Q1 2022

May 12, 2022

SELL
$8.12 - $16.9 $226,815 - $472,067
-27,933 Reduced 0.54%
5,166,900 $45.5 Million
Q4 2021

Feb 10, 2022

SELL
$15.91 - $21.88 $2.67 Million - $3.68 Million
-167,973 Reduced 3.13%
5,194,833 $83.4 Million
Q3 2021

Nov 09, 2021

SELL
$19.74 - $28.7 $4.07 Million - $5.92 Million
-206,391 Reduced 3.71%
5,362,806 $112 Million
Q2 2021

Aug 11, 2021

BUY
$20.49 - $35.63 $114 Million - $198 Million
5,569,197 New
5,569,197 $150 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.